Original paper

Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA ‐A24‐positive pancreatic adenocarcinoma

Volume: 110, Issue: 8, Pages: 2378 - 2385
Published: Jul 23, 2019
Abstract
The prognosis of advanced pancreatic adenocarcinoma is still extremely poor. This study sought to determine the efficacy of, and immunological response to, peptide vaccination therapy in patients with this disease. In this multicenter randomized phase II study, patients with advanced pancreatic adenocarcinoma after gemcitabine and/or tegafur/gimeracil/oteracil were randomly assigned to 3 groups that each received a 2-step treatment course. In...
Paper Details
Title
Randomized phase II trial of survivin 2B peptide vaccination for patients with HLA ‐A24‐positive pancreatic adenocarcinoma
Published Date
Jul 23, 2019
Volume
110
Issue
8
Pages
2378 - 2385
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.